Whether Xospata will be able to produce results and receive reimbursement extensions this time is gaining attention.

Dailpharm’s coverage showed that the agenda on expanding reimbursement standards for Xospata will likely be deliberated by the Health Insurance Review and Assessment Service(HIRA) Cancer Disease Deliberation Committee. The drug had been first approved for reimbursement in March of last year, but demand had been rising for its improvement due to the low effectiveness of the set standards.

The drug is indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation (FLT3mut+). However, only patients who received allogene